Antisense K-ras RNA gene therapy - Silenseed

Drug Profile

Antisense K-ras RNA gene therapy - Silenseed

Alternative Names: KRASG12D-LODER; siG12D-LODER

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Silenseed
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action KRAS protein modulators; Ras gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer

Most Recent Events

  • 06 Feb 2018 Phase-II clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable) in USA (Intratumoural) (NCT01676259)
  • 11 Jan 2016 siG12D-LODER is in phase IIa development for Pancreatic cancer in Israel
  • 04 Jun 2013 Adverse events and efficacy data from a phase I/II trial in Pancreatic cancer presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top